|Bid||23.13 x 100|
|Ask||23.20 x 400|
|Day's Range||22.48 - 23.56|
|52 Week Range||4.72 - 27.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2017 - Jun 2, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.90|
Uniqure NV (NASDAQ: QURE ) shares slid 22 percent in two weeks with no fundamental changes, prompting a Janney analyst to recommend buying the dip. The Analyst Janney analyst Yun Zhong reiterated a Buy ...
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
~On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018. ~Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Data Expected by End of 2018. ~Expects IND Submission ...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 27, 2018-- uniQure N.V., a leader in human gene therapy, today announced that it will be featured in multiple presentations at upcoming medical, scientific ...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 01, 2018-- uniQure N.V., a leader in human gene therapy, today announced that members of company management or principal investigators will participate ...
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 22, 2018-- uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced ...
~Pivotal Trial in Hemophilia B on Track to Begin in Q3 2018, with Initial AMT-061 Clinical Data by Year End~. ~AMT-130 Expected to be First AAV-Based Gene Therapy for Huntington’ s Disease to Enter Clinic~. ...
Categories: Yahoo FinanceGet free summary analysis uniQure NV reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of uniQure NV – Amgen Inc., bluebird bio, Inc. and BioMarin Pharmaceutical Inc. (AMGN-US, BLUE-US and BMRN-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)
On a per-share basis, the Amsterdam-based company said it had a loss of 40 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Uniqure NV (NASDAQ:QURE) investors are overwhelmingly excited today after the drug maker announced advancement of AMT-061, a Padua variant FIX AAV5 gene therapy, in hemophilia B, into a pivotal phase 3 trial in 3Q18. Cowen analyst Ritu Baral commented, "Surprisingly to us, this payload change (Padua FIX variant has a 2 nucleotide change leading to a single amino acid substitution) will be allowed to start clinical trials under the same IND and maintain FDA Breakthrough Designation and EMA PRIME Designation granted to AMT-060. "We do note other than the 2 nucleotide substitution, AMT-060 and AMT-061 are otherwise structurally identical, which we find encouraging given the predictability and duration of response seen with AMT-060 as well as excellent safety and low population seropositivity to date.
On Thursday, shares of leading gene therapy company uniQure (QURE) are skyrocketing, up over 50% in morning trading after it announced that it will launch a pivotal study next year testing AMT-061, the company's promising gene therapy candidate to treat patients with hemophilia B.